Corcept Therapeutics Inc. diskutieren
Corcept Therapeutics Inc.
WKN: 529882 / Symbol: CORT / Name: Corcept / Aktie / Pharmazeutika / Small Cap /
39,63 €
0,25 %
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $45.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Sandler O'Neill.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $67.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $115.00 to $150.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $76.00 to $150.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $128.00 to $131.00. They now have an "overweight" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target lowered by analysts at HC Wainwright from $150.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $145.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) was given a new $105.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its price target lowered by analysts at HC Wainwright from $105.00 to $67.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target lowered by HC Wainwright from $67.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for CORT provided by MarketBeat
Neueste Beiträge
Benchmark_Co_ in Smith Micro Software diskutieren